Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2005

View Archived Issues

Activation of mGlu4 receptors - a pharmacological strategy against medulloblastoma

Hypoglycemic effects of FR-225654 in preclinical models of diabetes

Pimecrolimus reported effective in facial seborrheic dermatitis

Amarillo updates low dose oral interferon progress

A novel bimosiamose formulation reduces plaque thickness in psoriasis

NeoPharm establishes bioequivalence for LEP-ETU

LigoCyte receives NIH grant for intranasal anthrax vaccine

Positive results of phase III trial of oxymorphone ER

Genaissance enters into HAP technology license agreement with Sankyo

Phase II program cleared for cholesterol-lowering drug FM-VP4

Acadia receives milestone under Allergan collaboration

Allergan and GSK enter product agreements

Japanese National Institute of Infectious Diseases to study Ampligen

AVR-118 begins phase I study in type 2 diabetes patients

Barbeau Pharma progresses pipeline

EGF/gastrin combination, E1-INT, reverses hyperglycemia and increases beta-cell mass

CTB-Insulin oral vaccine produced in silkworm larvae protects NOD mice from autoimmune diabetes

Anti-IL-13 antibody (CAT-354) effective against allergic airway and esophageal inflammation in mice

Data on novel SERM LY-2066948.HCl

Stockholders of Salix and InKine approve merger

Five reports of Guillain-Barre syndrome following administration of Menactra

Oracea NDA submission accepted for review

Discontinuation of phase III Canvaxin study in stage III melanoma

European approval for Vasovist for magnetic resonance angiography

Update on the antiepileptic effects of adjunctive rufinamide

Antipsychotics demonstrate similar efficacy in schizophrenia patients

Intralesional bleomycin plus electroporation under evaluation for metastatic melanoma

Recent patents disclose novel analgesic agents

New antiinfective agents described in recent patents

New anticoagulants prepared and tested by Aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...